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Summary.-The metabolism of 2-[14C] folic acid has been studied in rats with an
implanted Walker 256 tumour and in a closely matched group of controls. In animals
with tumours, more ofthe labelled folic acid isconverted to 10-formyltetrahydrofolate
and 10-formylfolate than in normal animals. No 5-methyltetrahydrofolate could be
detected in tumour tissue, or in the livers oftumour-bearing animals.Whenamixture
of2-[14C]- and 3',5',9-[3H]-folic acid is given to tumour-bearing rats a similar pattern
of metabolites is found. There is apparently less scission of the folate molecule in
tumour-bearing rats than in normal rats.
FOLATES function as cofactors essential
for the biosynthesis of nucleic acids, and
as such are central to the metabolism of a
cell. There have been many reports about
changes in folate co-enzymes occurring in
neoplastic or rapidly proliferating tissue
(Barbiroli et al., 1975; Halpern et al., 1977;
Lepage et al., 1972) but little information
is available on changes occurring in folate
metabolism in the whole animal contain-
ing such tissues. Since folate antagonists
such as methotrexate haveprovedeffective
in controlling some malignant tumours in
humans, further work on the impact of
tumours on folate metabolism in the whole
animnal is needed.
This paper reports the results of experi-
ments on the metabolism of 2-[14C]-folic
acid in rats with an implanted Walker 256
tumour. Recently, fragmentation pro-
ducts of folates have been reported in rat
urine after doses of either 3',5',9-[3H]-folic
acid (Murphy et al., 1976) or a mixture of
2-[14C]- and 3',5',9-[3H]-10-formylfolate
tetraglutamate (Connor et al., 1977). We
therefore report the results ofexperiments
dosingamixture of2-[14C]- and3',5',9-[3H1]-
folic acid to rats with an implanted Walker
256 tumour.
MIATERIALS AND) METHODS
Animals.-Male Wistar rats (150-200 g
body wt) were used throughout. Rats with
implanted Walker 256 carcinomas were sup-
plied by Dr T. A. Connors of the Chester
Beatty Institute, London. To provide precise
controls, normal rats were also obtained from
the Chester Beatty Institute. Animals re-
ceived doses of 2-[14C]-folic acid (78 ,ug/kg
body wt) or a mixture of 3'.5',9-[3H]- and 2-
[14C]-folic acid (107-2 ,tg/kg body wt) either
orally or by i.p. injection. Animals were then
housed in cages (Jencons, Metabowls), de-
signed for the separate collection of urine
and faeces. At the end of the experiment
animals were killed and the liver and tumour
tissue removed for determination of radio-
active content.
Collection of urine and faeces-Urine was
collected into flasks containing 10 ml of phos-
phate buffer (pH 7-0) with 2% (w/v) sodium
ascorbate and 0-005%o (w/v) of dithiothreitol.
To prevent light degradation of folates the
flasks were surrounded by aluminium foil.
Collection flasks were changed 6 h, 24 h and
48 h after administration of the folie acid.
Faeces were collected for 48 h after adminis-
tration of the dose.
Preparation of liver and tumour extracts.
Hot and cold extracts of livers and tumours
prepared as described in Barford et al. (1977).IMPLANTED RAT TUMOUR AND FOLIC ACID METABOLISM
Determination of radioactivity.-Urine
samples were diluted to a known volume with
phosphate buffer (pH 7 0) containing 2% w/v
sodium ascorbate. 50 ,ul aliquots were re-
moved, placed in 10 ml of scintillation cock-
tail and counted in a Nuclear Enterprises NE
8310 scintillation counter. All samples were
counted in duplicate. Suitable corrections
were made for quenching and background.
For the determination of total radioactivity
in faeces, liver and tumour tissue, samples
were first freeze-dried and then ground to a
homogeneous powder. 100 mg samples were
oxidized (in triplicate) using a Beckman Bio-
logical Materials oxidizer. 14CO2 was collected
into 15 ml of absorber scintillation cocktail
(Fisons absorber P). Samples were counted
and suitable corrections were made for
quenching and background.
Column chromatography.-Urine samples
were chromatographed on 2 types of
column.
(i) DEAE cellulose (Whatman DE52).
Columns were equilibrated with0 05Msodium
phosphate buffer (pH 7 0) containing 0.005%
of dithiothreitol. Urine samples were diluted
to give a conductivity identical to that of
0-05M phosphate buffer (pH 7 0) before load-
ing on to the column. Columns were eluted
with a linear NaCl gradient of 0 to 1-OM in
0-05M phosphate buffer (pH 7.0) containing
0.005% ofdithiothreitol. The column effluent
was collected in 5 ml fractions and the total
radioactivity and conductivity of each frac-
tion was determined.
(ii) Sephadex G15 chromatography. Urine
samples (up to 20 ml) were chromatographed
on a column of Sephadex G15 (Pharmacia
Ltd., Uppsala, Sweden) 1.5 cm2x60 cm in
0-05M phosphate buffer (pH 7.0) containing
0-005% of dithiothreitol. Radioactivity was
eluted from columns using 0-05M phosphate
buffer (pH 7-0) containing 0.005% of dithio-
threitol. Five millilitrefractions werecollected
and total radioactivity in each fraction deter-
mined.
Unless otherwise stated, recovery of radio-
activity from columns was complete under
the above conditions. Identical gradients on
different ion-exchange columns were obtained
using an "LKB Ultragrad" gradient maker
(L.K.B. Produkter AB, S-161 25 Bromma 1,
Sweden). Chromatography columns were
calibrated with authentic folate monogluta-
mates.
Chemicals.-All chemicals used were of
"AnalaR" grade or its equivalent. 2-[14C]-
folic acid and 3',5',9-[3H]-folic acid were
obtained from the Radiochemical Centre,
Amersham, Bucks.
5-methyltetrahydrofolate, prepared by the
method of Blair and Saunders (1970) and 4a-
hydroxy-5-methyltetrahydrofolate, prepared
by the method of Gapski et al. (1971), were
supplied by Dr K. Ratanasthien. 10-formyl-
tetrahydrofolate was prepared from 5-formyl-
tetrahydrofolate by the method of Beavon
and Blair (1972). 10-Formylfolate was pre-
pared by the method of Blakley (1959).
RESULTS
Experiments with 2-[14C]-folic acid
Normal animals and animals with an
implanted Walker 256 carcinoma received
oral and i.p. doses of 2-[14C]-folic acid
(78 ,ug/kg body wt). Urine, faeces, livers
and tumours were assayed for total radio-
active content as described inthe materials
and methods section. After both oral and
i.p. administration of folic acid, consider-
able amounts of radioactivity are excreted
in the urine of both groups of animals
(Table I). After oral administration of
2-[14C] folic acid, 14% of the dose is
excreted in the urine of normal rats over
a 48 h period, and 20% is excreted in the
urine of tumour-bearing rats in the same
time. There is significantly more radio-
activity excreted in the urine of tumour-
bearing rats over 6-24 h after admini-
stration of the dose than in normal rats
(P < 0.005). The mean recovery of radio-
activity in faeces after an oral dose
ofradioactivity is 45% in normal rats and
38% in tumour-bearing rats, but there is
no significant difference between these re-
coveries. Forty-eight hours after adminis-
tration of the dose, radioactivity is found
retainedin livers ofboth groups ofanimals
and in tumour tissue.
The urinary excretion of radioactivity
in the 0-6 h urine samples is significantly
higher than in both normal and tumour-
bearing rats after an i.p. dose of 2-[14C]-
folic acid (P<0-001) but not significantly
different to an oral dose in the 6-24 h
urine samples. There is considerable exere-
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TABLE I.-Recovery of radioactivity in urine, faeces, livers and tumours of rats receiving
oral or i.p. doses of 14C-folic acid (s.e. in parentheses)
% of administered radioactivity
Method Liver wt Tumour
of dosage (g) wt (g)
Oral 9 8 8
(0.71)
Oral 8 -0 5 - 8
(0 39) (0.98)
i.p. 8-9
(0 87)
i.p. 7-4
(1 -3)
Urine
t A - Faeces
-6 h 6-24 h 24-48 h 0-48 h
6 3- 4-8 3-4 44 9
(1-9) (1-3) (0 3) (3 4)
6-5 11-4 1-3 37-8
(1-1 ) (1-5) (0*2) (2-6)
32-1
(4.1)
6-7 27-8
(1-9) (5 2)
4-3 0 4 20-9
(0-7) (0 2) (3 6)
6-5 0 9 13-9
(1-8) (0 3) (0 9)
Liver Tumour
48 h 48 h
15-3
(0 9)
15-0
(0 82)
14-8
(2 6)
14-5
(O 9)
4*0
(0 39)
6-9
(0 5)
tion of radioactivity in faeces after an i.p.
dose of folic acid. The normal rats excrete
approximately 20% of the dose in faeces
(Table I) whereas the tumour-bearing rats
excrete approximately 14%. There is sig-
nificantly more radioactivity exereted in
faeces after an oral than ani.p. dose offolic
acid (P<0101). Urine samples werepooled
and chromatographed on DEAE cellulose,
and Sephadex G15. Four 14C-labelled
metabolites, co-chromatographing with
4a -hydroxy - 5 -methyl -tetrahydrofolate,
10-formyltetrahydrofolate, 5-methyltetra-
hydrofolate and folic acid, were found in
0-6 h urine samples from both normal and
tumour-bearing rats. The metabolites were
not, however, present in the same amounts
in the 2 groups of animals. Tumour-bear-
ing rats excreted less unmetabolized folic
acid, 5-methyl-tetrahydrofolate and 4a-
hydroxy-5-methyltetrahydrofolate but
more 10-formyltetrahydrofolates than the
normal rats (Fig. 1). This difference
between normal and tumour-bearing rats
is more pronounced in the 6-24 h urine
samples (Fig. 2). Liver and tumour ex-
tracts, prepared by hot extraction pro-
cedures, were chromatographed on DEAE
cellulose and Sephadex G15. The retained
liver radioactivity from both normal and
tumour-bearing rats, and the radioactivity
in the tumours behaved on both columns
as a folate polyglutamate (Barford et al.,
1977).
Experiments with a mixture of 2-[14C]- and
3',5',9-[3H]-folic acid
Animals with an implanted Walker 256
carcinoma received oral doses of a mixture
of 2-[14C]-folic acid and 3',5',9-[3H]-folic
acid (107-2 ,ug/kg body wt). Total recovery
ofradioactivity in urine is shown in Table
II. Both 3H and 140 are- excreted in the
urine of these animals. There is some dis-
crepancy between the recovery of 3H and
14C in urine. More 3H than 14C is recovered
in the 0-6 h and 6-24 h samples, but less
3H than 14C in the 24-48 h sample. Pooled
urine samples were chromatographed on
DEAE cellulose and Sephadex G15. The
results obtained were substantially the
same as those obtained when animals were
given 2-[14C]-folic acid only. Dual-labelled
metabolites corresponding to 4a-hydroxy-
5-methyltetrahydrofolate, 10-formyltetra-
hydrofolate, 5-methyl-tetrahydrofolate
TABLE II.-Recovery of 3H and 14C in the urine of tumour-bearing rats given oral doses
ofamixtureof2-[14C]- and3',5',9-[3H]-folic acid (,ug/kgbodywt). Theresults are expressed
as percentage of the dose recovered in each sample (s.e. in parentheses)
0-6h
3H 14C
31-6 (4.5) 25-2 (3-4)
6-24 h
3H
. 14C
14-5 (2-2) 9-9 (1-4)
24-48 h
3H 14C
0x-7 (-) 3-6(0-5)
Total
3H 14C
46-8 (3 4) 38-7 (2 6)
Animals
Normal
8 animals
Tumour-
bearing
13 animals
Normal
8 animals
Tumour-
bearing
8 animals
Total
74-7
76-5
72-5
70 5
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FIG. 1.-DEAE-cellulose chromatograph of
0-6 h urine samples. Animals received oral
doses of 2-['4C]-folic acid (78 jug/kg body
wt). Urine samples were pooled and suitable
aliquots chromatographed. A, Samples
from normal rats; B, Samples from tumour-
bearing rats. Elution positions of authentic
folates. (1) 4a-Hydroxy-5-methyltetrahy-
drofolate; (2) 10-Formyltetrahydrofolate;
(3) 5-Methyltetrahydrofolate; (4) Folic acid.
and folic acid were detected. However,
metabolites labelled only with 3H appear
in both 0-6 and 6-24 h urine samples (Fig.
3), and a metabolite labelled only with
14C iS found in the 6-24 h urine sample.
The 3H-labelled metabolites chromato-
graph in the same place as p-amino-
benzoyl-L-glutamate and tritiated water.
The 14C-labelled metabolite has not been
identified.
Hot extracts of both tumour tissue and
livers from tumour-bearing animals were
chromatographed on Sephadex G15 and
DEAE cellulose, and on both chromato-
grams the major radioactive metabolite
behaved as a folate polyglutamate (Bar-
B.
0 0.2 0.4 0.6 0.8
NaCl(M)
1.0 1.2
FIG. 2.-DEAE-cellulose chromatograph of
6-24 h urine samples. Animals received oral
doses of 2-[14C]-folic acid (78 ,ug/kg body
wt). Urine samples were pooled and chro-
matographed. A, Samples from normal
rats; B, Samples from tumour-bearing rats.
Elution positions of authentic folates.
(1) 4a-Hydroxy-5-methyltetrahydrofolate;
(2) 10-Formyltetrahydrofolate; (3) 5- Me-
thyltetrahydrofolate; (4) Folic acid.
ford et al., 1977). Tumourandliverextracts
were prepared by cold extraction so that
polyglutamates were allowed to break
downandthenchromatographed onDEAE
cellulose and Sephadex G15. The major
metabolite in the liver extract was found
to be I0-formylfolate; notraceof5-methyl-
tetrahydrofolate was found in any liver
extract (Fig. 4). Cold extracts of tumour
tissue gave a chromatogram that was
different from that obtained from livers.
The major dual-labelled metabolite was
10-formyltetrahydrofolate, no 5-methyl-
tetrahydrofolate appearing on any chro-
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matograms. In addition, cold tumour
extracts contained compounds labelled
with 3H and 14C only. The 14C-labelled
metabolite has not been identified, but is
not the same as that in urine samples. The
3H-labelled metabolite chromatographs on
both columns in the same place as p-
aminobenzoyl-L-glutamate.
DISCUSSION
Both normal and tumour-bearinig rats
absorb considerable amounts of an oral
dose of 2-[14C]-folic acid. Some of the ab-
sorbed radio-activity appears in urine, but
there is no significant difference between
the recovery of radioactivity over 48 hi in
normal rats and in tumour-bearing rats. A
large amount ofthe dose is excreted in the
faeces, some of it presumably being un-
absorbed folic acid. After an i.p. dose of
2-[14C]-folic acid, a higher percentage of
the dose is excreted in the urine of both
normal and tumour-bearing animals than
after an oral dose. There are alsosignificant
quantities of radioactivity in the faeces of
both groups of animals. This radioactivity
cannot be unabsorbed folic acid; it must
be radioactivity that is excreted into the
intestine. The most likely way for radio-
activity to enter the gastrointestinal tract
is via the bile (Lavoie and Cooper, 1974).
It therefore seems likely that the large
amounts of radioactivity in the faeces of
rats which have had oral dose of 2-[14C]
folic acid arises both from unabsorbed folic
acid and from excretion of 14C-labelled
metabolites via the bile.
After an oral dose of 2-[14C]-folic acid,
10 - formyltetrahydrofolate, Oformylfo -
late, 5-methyltetrahydrofolate and 4-a-hy-
droxy-5-methyltetrahydrofolate were all
found in the urine of both normal and
tumour-bearing rats. There are, how-
ever, 2 major differences between normal
and tumour-bearing rats. Firstly, al-
though slightly more of the dose is
excreted in the urine of tumour-bearing
rats, proportionally less of this radio-
activity is unmetabolized folic acid, sug-
gesting a more rapid metabolism of folic
9
acid to reduced folates in these animals.
Secondly, the major urinary metabolite in
the urine of normal rats is 5-methyltetra-
hydrofolate or 4a-hydroxy-5-methyltetra-
hydrofolate, whereas the major urinary
metabolites in tumour-bearing rats are 10-
formylfolate and 10-formyltetrahydro-
folate. This finding is consistent with the
results of other workers (Grzelakowska-
Sztabert et al., 1976) who have shown that
10 - formyltetrahydrofolate - synthesizing
enzymes are increased in malignant con-
ditions.
The results obtained when tumour-
bearing rats were given an oral dose of a
mixture of 2-[14C]- and 3',5',9-[3H]-folic
acid are substantially the same as those
obtained following a dose of 2-[14C]-folic
acid. Two further points emerge from these
experiments. Firstly the discrepancy be-
tween 14C recovery and 3H recovery in-
the urine of these animals is less than that
found when a mixture of 2-[14C]- and
3',5',9-[3H]-folic acid is given to normal
rats (Barford and Blair, 1976). Secondly,
there is a peak of 3H unmatched by 14C,
that chromatographs in the same place on
both types of column as p-amino-benzoyl-
L-glutamate. In some urine samples, a 14C
fragment which has not yet been identified
was detected.
The folate content oflivers and tumours
was examined by both hot and cold extrac-
tion procedures. Hot extractionprocedures
showed that the folate content of livers
from bothnormalandtumour-bearing rats,
and of tumours was almost all present as
folate polyglutamate (Barford et al., 1977).
Cold extraction of livers from tumour-
bearing rats showed that the majority of
the radioactivity was 1O-formylfolate.
Chromatograms of cold tumour extracts
showed that the major folate was 10-
formyltetrahydrofolate and the presence
ofsubstantial amountsofscissionproducts.
5-Methyltetrahydrofolate was notdetected
in any tumour extracted, nor in any liver
extract from tumour-bearing rats.
The distribution of 5-methyltetrahydro-
folate and 10-formyltetrahydrofolate in
the urine of animals is consistent with
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current ideas on the biochemical roles of
these 2 compounds. 5-Methyltetrahy-
drofolate in serum is thought to be a pool
of folate available to the tissues, and its
concentration rises and falls with changing
environmental conditions (Ratanasthien
et al., 1974). In health 10-formyltetrahy-
drofolate levels are kept fairly constant
(Ratanasthien et al., 1974) but in certain
disease conditions characterized by an en-
hanced rate of cellular proliferation, 10-
formyl-tetrahydrofolate levels are in-
creased (Sotoyobashi et al., 1966; Ratanas-
thien et al., 1974; Stokes et al., 1975; Blair
1976) and this is reflected in increased
urinary excretion of 10-formylfolate and
10-formyltetrahydrofolate. Similarly, in
conditions where the total folate pool is
depleted (e.g. animals on methotrexate)
the 10-formylfolates are preferentially
formed from folic acid (Barford et at.,
1976).
It seems likely that preferential conver-
sion of folic acid into 10-formylfolates in
experiments of this type can reflect two
different situations. Firstly, in conditions
characterized by enhanced cellular pro-
liferation there is an increased require-
ment for 10-formyltetrahydrofolate for
nucleic-acid biosynthesis. The increased
10-formylfolate and 10-formyltetrahydro-
folate levels in urine could be due either
to increased levels of l0-formyltetrahydro-
folate in the animal, or to an increased
rate ofturnover ofthe appropriate part of
the cellular cycle. Secondly, when total
folate pools are depleted, proportionally
more of the folic acid is converted into
10-formyltetrahydrofolate.
In the experiments described here, the
tumour weight was t,70% of that of the
liver, and could thus be expected to have
a pronounced effect on the metabolism of
the whole animal.
No 5-methyltetrahydrofolate was de-
tected in tumour extracts or in extracts
of liver from tumour-bearing animals.
Connor et al. (1977) have isolated the high-
mol-wt folate from livers of normal rats
and identified it by chemical methods as a
tetraglutamate of 10-formylfolate. 10-For-
mylfolatetetraglutamate is a powerful in-
hibitor of dihydrofolate reductase (Fried-
kin et al., 1975), while 10-formyltetrahy-
drofolate polyglutamates are not. This
may suggest a control mechanism be-
tween proliferating and non-proliferating
tissues.
The experiment using a mixture of 2-
[14C]- and 3',5',9-[3H]-folic acid demon-
strates that there is some scission of the
folate molecule in tumour-bearing animals,
but this scission is less than that found in
normal animals (Barford and Blair, 1976;
Barford et al., 1977). This may represent
a decreased catabolism of folates in
tumour-bearing animals.
The authors are grateful to the Cancer Research
Campaign for financial support and to the Royal
Society for a liquid scintillation counter.
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